Unknown

Dataset Information

A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients.


ABSTRACT:

Background

Dotinurad is a novel, selective urate reabsorption inhibitor (SURI), which reduces serum uric acid levels by selective inhibition of the urate transporter 1 (URAT1). The Japanese guideline for the management of hyperuricemia and gout recommends that drug selection should be based on classification of hyperuricemia as a fundamental principle. However, there may be some cases where this principle is not observed. We investigated the pharmacodynamics and safety of dotinurad in outpatients with uric acid overproduction or uric acid underexcretion type.

Methods

This was a multicenter, open-label, forced titration study. Patients were classified as uric acid overproduction or underexcretion type. Study treatment was initiated at 0.5 mg/day, followed by dose titration to

SUBMITTER: Hosoya T 

PROVIDER: S-EPMC7066296 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature